Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 0.8
Power Rank trend -> Rising
Industry: Biotechnology
Follow @stockchartsai on TwitterIn the past 20 trading days, MRVI has been trading in a range between $8.50 and $7.02 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Maravai Lifesciences Holdings Inc $MRVI entered a Red zone 1 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $13, a potential upside of 155.91% from the recent price of 5.08. The stock is trading 127.36% (potential upside) below its 52 week high of $11.55 and 8.55 % (potential downside) above its 52 week low of $4.68 - based on the recent price.
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Deb Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - EVP and Chief Financial Officer Drew Burch - President, Nucleic Acid Production Conference Call Participants Dan Leonard - UBS Justin Bowers - Deutsche Bank Yuko Oku - Morgan Stanley Matt Hewitt - Craig-Hallum Dan Arias - Stifel Operator Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. Source: Seeking Alpha Sat, 09 Nov 2024 18:45:06 -0500 Sentiment: Neutral |
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research. Source: Business Wire Thu, 07 Nov 2024 16:01:00 -0500 Sentiment: Neutral |
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024 SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. Source: GlobeNewsWire Tue, 15 Oct 2024 16:05:00 -0400 Sentiment: Neutral |
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity. Source: Zacks Investment Research Thu, 29 Aug 2024 10:25:45 -0400 Sentiment: Positive |
Exclusive: Repligen in bid for reagent vendor Maravai, sources say Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday. Source: Reuters Fri, 16 Aug 2024 11:46:16 -0400 Sentiment: Positive |
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.